Logo

Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Share this
Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Shots:

  • Polpharma Biologics has reported that its JV company- Bioeq collaborates with Teva to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU- Canada- Israel & New Zealand
  • The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis while FYB201 was originally licensed from Formycon AG
  • The recent agreement with Teva complements a previous agreement with Coherus BioScience for commercialization in the US. Lucentis is a mAb fragment that has been approved to treat wet AMD

  Ref: Businesswire | Image: Bioeq

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions